Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Research Area(s) / Expertise: Job title: Electrophysiologist and Clinical Researcher
A Mark Richards
Job title: Director of the Christchurch Heart Institute
Professor A. Mark Richards MD(Otago) PhD(Otago) FRACP is director of the Christchurch Heart Institute. Dr Richards also holds joint appointments at the University of Otago and the National University of Singapore’s Cardiovascular Research Institute. Research interests Neurohormonal physiology and pathophysiology in cardiovascular health and disease Heart Failure Acute Coronary Syndromes… View more
William T Abraham
Research Area(s) / Expertise:

Heart Failure

 Job title: Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine
Prof Abraham is a College of Medicine Distinguished Professor. He has been recognized as one of the “Best Doctors in America” for 18 consecutive years.His research has led to the approval/adoption of new heart failure therapies, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, ultrafiltration, implantable hemodynamic monitoring, transvenous phrenic nerve… View more
Antoni Bayés-Genís
Research Area(s) / Expertise: Job title: Head of the Cardiology Department
Antoni Bayés-Genís is Head of the Heart Institute at the University Hospital Germans Trias i Pujol in Barcelona, and Professor of Cardiology at the Universitat Autònoma de Barcelona in Barcelona, Spain.Prof Bayés-Genís is an expert on biomarker, including natriuretic peptides ST2 and neprilysin, having lectured on the subject at numerous international meetings and generated research data that… View more
AHA 23: KABUKI: DOAC in Pts with CTEPH
Author(s): Kazuya Hosokawa , Abe Kotaro Added: 1 year ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3… View more

Prevention & Chronic Conditions
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 4 weeks ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Survey on Interdisciplinary Management of Cardiotoxicity in Outpatient Sett
Author(s): Silvio Quick , Lorena Payo-Anez , Clara Marx Casimiro de Almeida , et al Added: 2 months ago

Guidelines & Statements

Imaging & Diagnostics
EASD 24: Effectiveness of Empagliflozin and GLP1s
Author(s): Phyo Htoo Added: 8 months ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Emerging Toxicities, Translational Research and Reverse Cardio-oncology
Author(s): Massimiliano Camilli , Luca Maggio , Lorenzo Tinti , et al Added: 1 month ago

CV Disease in Special Populations

Heart Failure
Cardiac Involvement Due to COVID-19
Author(s): Valentina O Puntmann , Anastasia Shchendrygina , Carlos Rodriguez Bolanos , et al Added: 1 year ago

Imaging & Diagnostics

COVID-19